These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36706970)

  • 1. Poly (amino acid)s as new co-formers in amorphous solid dispersion.
    Huang Q; Zou Z; Li X; Xiao Q; Liang G; Wu W
    Int J Pharm; 2023 Mar; 634():122645. PubMed ID: 36706970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleotides as new co-formers in co-amorphous systems: Enhanced dissolution rate, water solubility and physical stability.
    Liu X; Shen L; Zhou L; Wu W; Liang G; Zhao Y; Wu W
    Eur J Pharm Biopharm; 2024 Jul; 200():114333. PubMed ID: 38768766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems.
    Wu W; Löbmann K; Rades T; Grohganz H
    Int J Pharm; 2018 Jan; 535(1-2):86-94. PubMed ID: 29102703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptides as co-formers in co-amorphous systems.
    Wu W; Löbmann K; Schnitzkewitz J; Knuhtsen A; Pedersen DS; Rades T; Grohganz H
    Eur J Pharm Biopharm; 2019 Jan; 134():68-76. PubMed ID: 30468836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers.
    Wu W; Grohganz H; Rades T; Löbmann K
    Eur J Pharm Sci; 2021 Jan; 156():105582. PubMed ID: 33039568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
    Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
    Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissolution changes in drug-amino acid/biotin co-amorphous systems: Decreased/increased dissolution during storage without recrystallization.
    Zou Z; Huang Q; Li X; Liu X; Yin L; Zhao Y; Liang G; Wu W
    Eur J Pharm Sci; 2023 Sep; 188():106526. PubMed ID: 37442486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
    Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
    J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-former selection for co-amorphous drug-amino acid formulations.
    Kasten G; Löbmann K; Grohganz H; Rades T
    Int J Pharm; 2019 Feb; 557():366-373. PubMed ID: 30578980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sinapic Acid Co-Amorphous Systems with Amino Acids for Improved Solubility and Antioxidant Activity.
    Garbiec E; Rosiak N; Tykarska E; Zalewski P; Cielecka-Piontek J
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Effects of Supersaturation Rates and Doses on the Kinetic-Solubility Profiles of Amorphous Solid Dispersions Based on Water-Insoluble Poly(2-hydroxyethyl methacrylate) Hydrogels.
    Schver GCRM; Lee PI
    Mol Pharm; 2018 May; 15(5):2017-2026. PubMed ID: 29601723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amorphous solid dispersions of lidocaine and lidocaine HCl produced by ball milling with well-defined RAFT-synthesised methacrylic acid polymers.
    Bakhtiari SE; Zhu Z; Magdysyuk OV; Brocchini S; Williams GR
    Int J Pharm; 2023 Sep; 644():123291. PubMed ID: 37544388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced dissolution rate of nimodipine through β-lactoglobulin based formulation.
    Leng D; Bulduk B; Anlahr J; Müllers W; Löbmann K
    Int J Pharm; 2023 Mar; 635():122693. PubMed ID: 36754186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspartame as a co-former in co-amorphous systems.
    Wu W; Löbmann K; Schnitzkewitz J; Knuhtsen A; Pedersen DS; Grohganz H; Rades T
    Int J Pharm; 2018 Oct; 549(1-2):380-387. PubMed ID: 30075253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine.
    Kasten G; Nouri K; Grohganz H; Rades T; Löbmann K
    Int J Pharm; 2017 Nov; 533(1):138-144. PubMed ID: 28947246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Counterions on Dissolution of Amorphous Solid Dispersions Studied by Surface Area Normalized Dissolution.
    Chen Y; Lubach JW; Tang S; Narang AS
    Mol Pharm; 2021 Sep; 18(9):3429-3438. PubMed ID: 34338529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining enabling formulation strategies to generate supersaturated solutions of delamanid: In situ salt formation during amorphous solid dispersion fabrication for more robust release profiles.
    Duong TV; Nguyen HT; Taylor LS
    Eur J Pharm Biopharm; 2022 May; 174():131-143. PubMed ID: 35413402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance.
    Indulkar AS; Lou X; Zhang GGZ; Taylor LS
    Mol Pharm; 2019 Mar; 16(3):1327-1339. PubMed ID: 30669846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining drug salt formation with amorphous solid dispersions - a double edged sword.
    Hiew TN; Taylor LS
    J Control Release; 2022 Dec; 352():47-60. PubMed ID: 36206947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.